Brief: U.S. FDA Accepts Bristol Myers Squibb's NDA For Iberdomide In Multiple Myeloma
17/02/2026 15:38
Feb 17 (Reuters) - FDA: U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL MYERS SQUIBB'S NEW DRUG APPLICATION FOR IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA BRISTOL-MYERS SQUIBB CO: U.S. FDA ASSIGNS A TARGET ACTION DATE OF AUGUST 17, 2026, GRANTS BREAKTHROUGH THERAPY DESIGNATION & PRIORITY REVIEW Further company coverage: BMY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC